Open Menu

Diagnostic Approach to Cephalosporin Allergy Testing (DACAT Trial)

Study Info

Started In 2025

Sites 7

Target Enrollment: 300 participants


About the study

DACAT is a multi-site clinical trial (NCT06406114) designed to improve the diagnosis of cephalosporin allergy. Because cephalosporins share similar chemical structures, many patients are unnecessarily labeled as allergic and restricted from using these important antibiotics. This study will enroll 300 participants across sites and use standardized double-blind skin testing and drug challenges to confirm or rule out suspected cephalosporin allergy and to develop an optimal, evidence-based diagnostic approach.

Learn more at DACAT – Massachusetts General Hospital and  Study Details | NCT06406114 | Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing | ClinicalTrials.gov

Participating Sites

Mayo Clinic Florida
Mayo Clinic Arizona
Massachusetts General Hospital
Rochester Regional Health
Vanderbilt University
University of Texas Southwestern Medical Center
University of California San Francisco

Team Members

Mayo Clinic Florida
PI
Kimberly Blumenthal, MD, MSc
Mayo Clinic Arizona
Site PI
Alexei Gonzalez Estrada, MD
Massachusetts General Hospital
Site PI
Aleena Banerji, MD
Rochester Regional Health
Site PI
Allison Ramsey, MD
Vanderbilt University
Site PI
Elizabeth Phillips, MD
University of Texas Southwestern Medical Center
Site PI
David Khan, MD
University of California San Francisco
Site PI
Iris Otani, MD